DirectorsTalk Interviews brings investors closer to the people behind listed companies, markets and sectors. We feature interviews with CEOs from UK, US and Canadian companies, alongside fund managers, analysts and sector specialists, giving audiences direct insight into strategy, performance, opportunities and risks. Each interview is designed to help investors understand the businesses shaping the market and make more informed decisions.
Non-Standard Finance plc (LON: NSF) is the topic of conversation when Mark Thomas, Analyst at Hardman & Co joins DirectorsTalk. Mark explains why he called his recent report ‘Sunshine after..
CentralNic Group plc (LON: CNIC) CEO Ben Crawford joins DirectorsTalk to discuss its trading for both Q4 and FY 2019. Ben talks us through the key highlights, explains what area..
Vertu Motors plc (LON: VTU) is the topic of conversation when Mike Allen, Head of Research at Zeus Capital caught up with DirectorsTalk. Mike shares his thoughts on a Systems..
Avacta Group plc (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss an agreement with AffyXell in S Korea. Alastair talks us through the details, explains the main focus for..
SimplyBiz Group (LON: SBIZ) is the topic of conversation when Robin Savage, Analyst at Zeus Capital talks to DirectorsTalk. Robin talks us through the key points from its year end..
Avacta Group (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the successful initial proof-of-concept for a proprietary new class of anti-cancer therapy. Alastair explains what a TMAC drug conjugate..
Jubilee Metals Group (LON: JLP) CEO Leon Coetzer joins DirectorsTalk to discuss its six month operations update. Leon talks us though the highlights, explains how Chrome and PGM operations have..
Norman Broadbent (LON: NBB) CEO Mike Brennan talks to DirectorsTalk about its latest trading update. Mike talks us through the key highlights, his confidence for the future, moving to larger..
JTC Group plc (LON: JTC) is the topic of conversation when Robin Savage Analyst at Zeus Capital joins DirectorsTalk. Robin talks us through the key points from the year end..
Ilika plc (LON: IKA) is the topic of conversation when Dr Tom McColm Partner and Clean Tech Equity Specialist at Baden Hill provides his view on the company’s results. Tom..
Avacta plc (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss its trading update for the 17 month period ended 31 December 2019. Alastair explains why its a 17 month..
Cambria Automobiles (LON: CAMB) is the topic of conversation when Mike Allen, Head of Research at Zeus Capital joins DirectorsTalk. Mike shares his thoughts on the acquisition of two new..
DWF Group (LON: DWF) is the topic of conversation when Mike Allen, Head of Research at Zeus Capital caught up with DirectorsTalk. Mike talks us through the key points to..
Manolete Partners (LON: MANO), the leading UK-listed insolvency litigation financing company, has published its latest investor presentation. Manolete Partners Plc operates as an insolvency litigation financing company in the United..
Hardman & Co CEO Keith Hiscock joins DirectorsTalk to discuss his latest report entitled “Share ownership: for the many, not the few?” Keith explains the meaning behind the title, the..
Touchstone Exploration (LON: TXP) CEO Paul Baay joins DirectorsTalk to discuss its update on the Cascadura well. Paul talks us through the highlights, explains the next steps, what this means..
RM Secured Direct Lending PLC (LON: RMDL) is the topic of conversation today when Mark Thomas, Analyst at Hardman & Co joins DirectorsTalk. Mark talks us through his conclusions from..
City of London Investment Group (LON: CLIG) is the topic of conversation when Robin Savage, Research Analyst at Zeus Capital joins DirectorsTalk. Robin talks us through the key points from..
Real Estate Credit Investments (LON: RECI) is the topic of conversation with Mark Thomas analyst at Hardman & Co. Mark explains why he called his recent piece ‘Delivering on its..
Avacta Group (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss it’s JV with Daewoong Pharmaceuticals in South Korea. Alastair explains what the JV will be focused on, expands on..
